Pediatric Oncology Imaging Guidelines

The eviCore Pediatric Oncology Imaging Guidelines approve modality-specific advanced imaging (MRI preferred for CNS/musculoskeletal disease, CT for chest/abdomen/pelvis and lymphoma/solid tumor staging, 123I‑MIBG for neuroblastoma) while generally excluding routine advanced imaging in asymptomatic children, PET/CT for lesions <8 mm or routine surveillance, and PET/MRI except in tightly restricted circumstances and other modality‑specific limitations. Approvals require documented recent clinical evaluation (≤60 days), histologic confirmation/staging or disease‑specific exceptions, and specific supporting documentation (clinical decision justification for PET/PET‑MRI, genetic confirmation or specialist diagnosis for predisposition screening, ANC <500 for infection imaging in immunocompromised patients, and adherence to stated timing/frequency constraints such as delaying PET ≥12 weeks after radiation unless urgent).

"PEDONC-2."